Loading...

Background

Why was GAFIO established

The global incidence of cancer continues to rise, both in high-income countries and, especially, in low- and middle-income countries. In 2020, there were approximately 19.3 million newly diagnosed cancer cases, and 10.0 million cancer-related deaths worldwide. By 2050, the number of cancer cases is predicted to increase 77% to 35 million cases. Meanwhile, the economic cost for cancer treatment and care has been escalating 6%-9% annually, standing at around US$550 billion as of 2020. Moreover, geographic and economic barriers result in significant disparities in cancer survival rates between high-, middle- and low-income countries, for instance 67% in the US, 50% in India, and as low as 30% in sub-Saharan Africa. The escalating cost and complexity of cancer treatment necessitate a radical transformation in cancer care.

19.3 M

diagnosed cancer

10.0 M

related deaths

550 B USD

economic cost

9.0 %

escalating annually

GAFIO offers three types

Membership Types

Professional Background: Individuals applying for membership should have a background or interest in oncology, informatics, artificial intelligence, or related fields.
Qualifications: Applicants may be required to hold a bachelor's degree or higher in a relevant field, such as medicine, informatics, engineering, or related disciplines.
Commitment to GAFIO’s Mission: Prospective members should support GAFIO's mission and goals, which often involve advancing oncology, AI, and patient care through education, research, and collaboration.
Relevant Experience: While not always mandatory, having professional experience or involvement in oncology or AI-related activities can strengthen an individual's application for membership.

Relevant Background:  Open to residents, fellows, and students enrolled in relevant undergraduate, graduate, doctoral, post-doctoral, or resident training programs.
Commitment to GAFIO’s Mission: Prospective members should support GAFIO's mission and goals, which often involve advancing oncology, AI, and patient care through education, research, and collaboration.

Organizational Profile: Corporate members are typically entities such as hospitals, medical institutions, research organizations, and companies involved in healthcare, oncology, AI, or related industries.
Commitment to GAFIO's Mission: Similar to individual members, corporate members should align with GAFIO's mission and goals, especially in areas related to oncology, AI, and healthcare innovation.
Legal Entity Status: Corporate members must have legal entity qualifications or represent social groups with an interest in oncology, AI, or related social welfare activities.
Financial Commitment: Corporate members may be required to pay membership dues or fees based on their organizational size or membership tier.

Latest News

5/10/2026
New Transformer‑Based TSMIL Framework Achieves State‑of‑the‑Art Accuracy for Renal Cell Carcinoma Classification in Whole‑Slide Images

Renal cell carcinoma accounts for nearly 90 % of kidney cancers, and accurate histopathological subtyping is crucial for diagnosis, prognosis, and treatment. However, the gigapixel size of WSIs and the lack of pixel‑wise annotations make traditional deep‑learning approaches challenging. Most existing multiple instance learning methods treat tissue patches independently, losing global contextual dependencies and struggling with class imbalance or indistinct tumour boundaries. A research team from Chongqing University, Peking University School and Hospital of Stomatology & NHC Key Laboratory of Digital Stomatology, and The Hong Kong Polytechnic University has developed TSMIL-a Transformer‑based structured low‑rank multiple instance learning network. Published in Intelligent Oncology.

Read More
4/28/2026
Intelligent Oncology Officially Indexed in DOAJ

Recently, the Editorial Office of Intelligent Oncology received a notification from the DOAJ Team that, after rigorous evaluation, the journal has been officially indexed in DOAJ, the world’s most influential open access journal database.

Read More
4/20/2026
New review highlights how hNQO1‑activatable NIR‑II probes and artificial intelligence are advancing precision oncology

A new review published in Intelligent Oncology (Volume 2, Issue 2, 2026) highlights a powerful convergence of molecular imaging and artificial intelligence that could reshape how we detect, visualize, and treat cancer. Led by David B. Olawade (University of East London) and an international research team, this work explores the emerging role of hNQO1-activatable NIR-II fluorescent probes in precision oncology.

Read More

Becoming a member

If you have a common vision with us, join us

Image

Please fill out the form

Fill in this information to help us understand you and create a private profile for you.

Email available
Email unavailable
Get
Verification code required
Password required
Confirm password required
Please select country or region
Please select member type
First Name required
Last/Family Name required
Please select gender
Please select Academic Degree
Affiliation required
Major Focus required
Cancer Subspecialties required